Addressing Doxorubicin Resistance in Bone Sarcomas Using Novel Drug-Resistant Models

Bone sarcomas have not shown a significant improvement in survival for decades, due, in part, to the development of resistance to current systemic treatments, such as doxorubicin. To better understand those mechanisms mediating drug-resistance we generated three osteosarcoma and one chondrosarcoma c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallego, Borja, Murillo, Dzohara, Rey, Verónica, Huergo, Carmen, Estupiñán, Óscar, Rodríguez, Aida, Tornín, Juan, Rodríguez, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224263/
https://www.ncbi.nlm.nih.gov/pubmed/35742867
http://dx.doi.org/10.3390/ijms23126425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224263/
https://www.ncbi.nlm.nih.gov/pubmed/35742867
http://dx.doi.org/10.3390/ijms23126425

Ejemplares similares